Photo from wikipedia
Low‐dose azacitidine (AZA) regimens, primarily 5‐day AZA, have been used in lower risk myelodysplastic syndrome (LrMDS) but they have yet to be directly compared to the standard 7‐day, uninterrupted dosing… Click to show full abstract
Low‐dose azacitidine (AZA) regimens, primarily 5‐day AZA, have been used in lower risk myelodysplastic syndrome (LrMDS) but they have yet to be directly compared to the standard 7‐day, uninterrupted dosing schedule.
Keywords:
day;
five day;
risk myelodysplastic;
myelodysplastic syndrome;
lower risk
Journal Title: Cancer
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Cancer
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!